scholarly journals Ancillary Testing in Lung Cancer Diagnosis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
William Dubinski ◽  
Natasha B. Leighl ◽  
Ming-Sound Tsao ◽  
David M. Hwang
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics ◽  
Cancer Diagnosis ◽  
Targeted Therapies ◽  
Patient Management ◽  
Predictive Information ◽  
Lung Cancers ◽  
Pathologic Diagnosis ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.

An Automated Computer System Based on Genetic Algorithm and Fuzzy Systems for Lung Cancer Diagnosis

2018 ◽  
Vol 19 (6) ◽  
pp. 583-594 ◽  
Author(s):  
Abir Alharbi
Keyword(s):  
Lung Cancer ◽  
Real Data ◽  
Classification Performance ◽  
Automated System ◽  
Lung Cancers ◽  
Cancer Data ◽  
Lung Cancer Diagnosis ◽  
Degree Of Confidence ◽  
Diagnosis Of Lung Cancer ◽  
Rule System

AbstractAn automated system for the diagnosis of lung cancer is proposed in this paper, the system is designed by combining two major methodologies, namely the fuzzy base systems and the evolutionary genetic algorithms (GAs), to be employed on lung cancer data to assist physicians in the early detection of lung cancers, and hence obtain an early automated diagnosis complementary to that by physicians. Our hybrid algorithm, the genetic-fuzzy algorithm, has produced optimized diagnosis systems that attain high classification performance, in fact, our best six rule system obtained a 97.5 % accuracy, with simple and well interpretive rules, with 93 % degree of confidence, and without the need for dimensionality reduction. The results on real data indicate that the proposed system is very effective in the diagnosis of lung cancer and can be used for clinical applications.

scholarly journals Considering Patients’ Mental Capacity When Giving Them Bad News May Help Their Well-Being: A Case of Suicide Attempt after Being Informed of Lung Cancer Diagnosis

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Toshiyuki Kobayashi ◽  
Satoshi Kato ◽  
Mitsuo Takeuchi
Keyword(s):  
Lung Cancer ◽  
Suicide Attempt ◽  
Cancer Diagnosis ◽  
Attempted Suicide ◽  
Well Being ◽  
Mental Capacity ◽  
Bad News ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Mental Well Being

Mental capacity is a central determinant of patients’ ability to make autonomous decisions about their care and deal with bad news. Physicians should be cognizant of this when giving patients bad news in efforts to help them to cope with the illness and to avoid a deterioration of their mental well-being. To show the importance of this concept, a case of suicide attempt with lung cancer is exemplified. A 76-year-old woman attempted suicide after receiving a diagnosis of lung cancer. Her recent life had been emotionally turbulent and she did not have sufficient mental capacity to accept and cope with this truth. She developed depression before attempting suicide.

scholarly journals Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ji Young Park ◽  
Ye Jin Lee ◽  
Taehee Kim ◽  
Chang Youl Lee ◽  
Hwan Il Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Rapid Progression ◽  
Lung Cancers ◽  
The Past ◽  
Lung Cancer Diagnosis ◽  
Number Of Patients ◽  
Wide Range ◽  
Collateral Effects ◽  
The Impact

Abstract Background The COVID-19 pandemic is predicted to significantly affect patients with lung cancer, owing to its rapid progression and high mortality. Studies on lung cancer diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 on lung cancer diagnosis in Korea, where lung cancer incidence continues to rise. Methods The number of newly diagnosed lung cancer cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer cases diagnosed during the same period in the past 3 years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed. Results A total of 612 patients were diagnosed with lung cancer from February through June, 2017–2020. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection symptoms. Wide-range screening and preventive measures were implemented, thus minimizing the delay in lung cancer diagnosis. No patient acquired COVID-19 due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer (NSCLC) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p = 0.011). The number of lung cancers diagnosed during this period and the previous year remained the same. Conclusions The proportion of patients with advanced NSCLC increased during the COVID-19 pandemic.

scholarly journals Challenges in lung cancer diagnosis during the outbreak of COVID-19

2020 ◽  
Author(s):  
chunhua xu ◽  
wei wang ◽  
li li ◽  
jiwang wang
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Needle Biopsy ◽  
Transbronchial Biopsy ◽  
Public Health Emergency ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Novel Coronavirus ◽  
Individualized Management

A pandemic of 2019 novel coronavirus diseases (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.

scholarly journals Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shinechimeg Dima ◽  
Kun-Huang Chen ◽  
Kung-Jeng Wang ◽  
Kung-Min Wang ◽  
Nai-Chia Teng
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Physician Visits ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Kaplan Meier ◽  
Diagnosis Of Lung Cancer

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.

scholarly journals Cryobiopsy in Lung Cancer Diagnosis—A Literature Review

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 393
Author(s):  
Mărioara Simon ◽  
Ioan Simon ◽  
Paul Andrei Tent ◽  
Doina Adina Todea ◽  
Antonia Haranguș
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Diagnostic Yield ◽  
Lung Tumors ◽  
Small Sample ◽  
Diagnostic Methods ◽  
Endobronchial Ultrasound ◽  
Forceps Biopsy ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

Optimizing the diagnosis of lung cancer represents a challenge, as well as a necessity, for improving the low survival of these patients. Flexible bronchoscopy with forceps biopsy is one of the key diagnostic procedures used for lung tumors. The small sample size and crush artifacts are several factors that can often limit access to a complete diagnosis, therefore leading to the need of repeating the bronchoscopy procedure or other invasive diagnostic methods. The bronchoscopic cryobiopsy is a recent technique that proved its utility in the diagnosis of both endobronchial and peripheral lung tumors. In comparison with conventional forceps biopsy, studies report a higher diagnostic yield and a superior quality of the collected samples for both the histopathological and the molecular diagnosis of lung cancer. This method shows promising results in sampling lung tissue, alone, or in conjunction with fluoroscopy or radial endobronchial ultrasound (r-EBUS). With a good safety and cost-benefit profile, this novel method has the potential to improve the diagnosis, and therefore the management of lung cancer patients. The objective of this narrative review is to provide a comprehensive review of the recent data regarding the advantages of cryobiopsy and r-EBUS in lung cancer diagnosis.

scholarly journals Diagnostic efficacy cell block method of transthoracic fine needle aspiration in diagnosis of lung cancer

2021 ◽  
Vol 40 (2) ◽  
pp. 133-140
Author(s):  
Yusup Subagio Sutanto ◽  
Nur Santi ◽  
Brian Wasita ◽  
Ana Rima ◽  
Hendra Kurniawan
Keyword(s):  
Lung Cancer ◽  
Sensitivity And Specificity ◽  
Cancer Diagnosis ◽  
Fine Needle Aspiration ◽  
Needle Aspiration ◽  
Cell Block ◽  
Fine Needle ◽  
Lung Cancer Diagnosis ◽  
Bronchial Washing ◽  
Diagnosis Of Lung Cancer

BackgroundLung cancer is still the main cause of cancer deaths. The high lung cancer mortality rate is caused by a diagnosis factor or therapy selection. The cell block cytology technique using fine needle aspiration (FNA) samples can provide immunocytochemical material that plays an important role in the differential diagnosis of lung cancer subtypes and in determining immunotherapy administration. This study aimed to determine the sensitivity and specificity of transthoracic FNA (TTFNA) cell block cytology in comparison with bronchial washing smears and TTFNA smears in diagnosing lung cancer. MethodsThis was a cross-sectional diagnostic study involving 26 subjects. All subjects had undergone bronchial washing and CT scan-guided fine needle aspiration followed by cell block preparation. Both direct FNA smears and cell blocks are useful in the diagnostic work-up of patients. Comparative statistical analysis of TTFNA cell block versus bronchial washing smear and TTFNA smear cytology was carried out using the McNemar test. ResultsLung cancer was found in 15 patients (57.7%) using the TTFNA cell block technique. The sensitivity and specificity of the TTFNA cell block technique were 85.7% and 75%, respectively. There was no difference in the positivity value between TTFNA cell block technique of bronchial wash smear technique, and TTFNA smear on lung cancer diagnosis (p>0.05). ConclusionsTransthoracic fine-needle aspiration in combination with the cell block technique has good sensitivity and specificity. The TTFNA can be used for immunocytochemical examinations in lung cancer diagnosis and therapy. This approach is valuable for providing individualized treatment and prognostic evaluations.

scholarly journals Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society

2016 ◽  
Vol 140 (11) ◽  
pp. 1267-1272 ◽  
Author(s):  
Sinchita Roy-Chowdhuri ◽  
Dara L. Aisner ◽  
Timothy Craig Allen ◽  
Mary Beth Beasley ◽  
Alain Borczuk ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Carcinoma ◽  
Large Fraction ◽  
Molecular Testing ◽  
Lung Cancers ◽  
Cancer Management ◽  
Lung Cancer Diagnosis ◽  
Therapeutic Decisions ◽  
Biomarker Testing ◽  
Diagnosis Of Lung Cancer

The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

Sign in / Sign up

Export Citation Format

Share Document